Canick Jacob A, Saller Devereux N, Lambert-Messerlian Geralyn M
Division of Prenatal and Special Testing, Department of Pathology and Laboratory Medicine, Women and Infants Hospital, Brown Medical School, Providence, RI 02905, USA.
Clin Lab Med. 2003 Jun;23(2):395-411. doi: 10.1016/s0272-2712(03)00025-8.
Second-trimester serum screening for Down syndrome has had a relatively long clinical life, beginning in the mid-1980s and continuing to the present day. In the past few years, however, new screening methods that involve testing just a few weeks earlier and the integration of first-trimester and second-trimester markers have been proposed and are being used. These improved methods have begun the transition to better and, hopefully, safer prenatal screening. In the past, as many as 1 in 10 pregnant women learned that they were at increased risk of having a baby with a serious birth defect and had to decide whether to have an invasive diagnostic procedure. Now, screening methods are at the point where as few as 1 in 50 or 1 in 100 pregnant women are found to be at increased risk. The ultimate goal in screening is to make noninvasive testing methods so safe that only those few women who are found to be at the very highest risk will need to face the uncertainty of invasive procedures. In the next few years, that goal will probably be achieved.
孕中期唐氏综合征血清筛查已有较长的临床应用历史,始于20世纪80年代中期,一直持续到现在。然而,在过去几年中,已经提出并正在使用一些新的筛查方法,这些方法只需在孕早期提前几周进行检测,并整合了孕早期和孕中期的标志物。这些改进的方法已开始向更好、有望更安全的产前筛查过渡。过去,每10名孕妇中就有多达1人得知自己生下患有严重出生缺陷婴儿的风险增加,不得不决定是否进行侵入性诊断程序。现在,筛查方法已达到这样的程度,即每50或100名孕妇中只有1人被发现风险增加。筛查的最终目标是使非侵入性检测方法非常安全,以至于只有极少数被发现风险极高的女性才需要面对侵入性程序的不确定性。在未来几年,这个目标可能会实现。